$The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo$

The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo

Background: Radiotherapy has a high curative potential in localized prostate cancer, however, there are still patients with locally advanced tumours who face a considerable risk of recurrence. Radiosensitization using molecular targeted drugs could help to optimize treatment for this high-risk group...

Full description

Bibliographic Details
Main Authors:	Steffi Liebscher, Lydia Koi, Steffen Löck, Michael H. Muders, Mechthild Krause
Format:	Article
Language:	English
Published:	Elsevier 2017-02-01
Series:	Clinical and Translational Radiation Oncology
Subjects:	Nelfinavir Prostate cancer Irradiation Radiosensitization Growth delay Local tumor control
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405630816300477

Similar Items

HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
by: Unaí Tupinambás, et al.

The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response
by: Anjali K. Gupta, et al.
Published: (2007-04-01)

The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir
by: Mahbuba R. Subeha, et al.
Published: (2020-11-01)

Efeitos da administração diária da associação estavudina/nelfinavir sobre os fetos e placentas da rata albina Effects of daily administration of a stavudine/nelfinavir association on the fetuses and placentas of female albino rats
by: Gisela Maria Vieira Rodrigues de Carvalho, et al.
Published: (2011-05-01)

Efeitos do uso crônico do nelfinavir sobre a prenhez da rata albina: ensaio biológico Effects of chronic nelfinavir treatment on rat pregnancy: biological assay
by: Camila Fernandes Venneri Mathias, et al.
Published: (2006-03-01)

The Effect of β-Carotene Supplementation on the Pharmacokinetics of Nelfinavir and Its Active Metabolite M8 in HIV-1-infected Patients
by: Humayoun Akhtar, et al.
Published: (2012-01-01)

Nelfinavir: An Old Ally in the COVID-19 Fight?
by: Anna Gidari, et al.
Published: (2022-12-01)

HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein
by: Zhongli Liu, et al.
Published: (2022-08-01)

Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil
by: T. Vanni, et al.
Published: (2007-07-01)

Nelfinavir inhibition of Kaposi’s sarcoma-associated herpesvirus protein expression and capsid assembly
by: Maggie Li, et al.
Published: (2024-03-01)

Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment
by: Henry D. McCann, et al.
Published: (2018-10-01)

Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma
by: Dominika Fassmannová, et al.
Published: (2020-04-01)

A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19
by: Taiga Miyazaki, et al.
Published: (2023-06-01)

Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells
by: Wei Liu, et al.
Published: (2018-11-01)

HIV Protease Inhibitors Decrease VEGF/HIF-1α Expression and Angiogenesis in Glioblastoma Cells
by: Nabendu Pore, et al.
Published: (2006-11-01)

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
by: Victoria Y. Strauss, et al.
Published: (2019-02-01)

Nelfinavir Induces Cytotoxicity towards High-Grade Serous Ovarian Cancer Cells, Involving Induction of the Unfolded Protein Response, Modulation of Protein Synthesis, DNA Damage, Lysosomal Impairment, and Potentiation of Toxicity Caused by Proteasome Inhibition
by: Mahbuba R. Subeha, et al.
Published: (2021-12-01)

Radiosensitization of PC3 Prostate Cancer Cells by 5-Thiocyanato-2′-deoxyuridine
by: Magdalena Zdrowowicz, et al.
Published: (2022-04-01)

Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts
by: Lydia Koi, et al.
Published: (2023-08-01)

Combination of Autophagy Selective Therapeutics With Doxil: An Assessment of Pathological Toxicity
by: Kristi L. Helke, et al.
Published: (2022-06-01)

Sensing HIV Protease and Its Inhibitor Using “Helical Epitope”—Imprinted Polymers
by: Chien-Yu Chou, et al.
Published: (2020-06-01)

Misfolded proteins: from little villains to little helpers in the fight against cancer
by: Ansgar eBrüning, et al.
Published: (2015-02-01)

Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma
by: Junbin Liao, et al.
Published: (2019-11-01)

Overexpression of IGFBP5 Enhances Radiosensitivity Through PI3K-AKT Pathway in Prostate Cancer
by: Chen X, et al.
Published: (2020-07-01)

Combined docking methods and molecular dynamics to identify effective antiviral 2, 5-diaminobenzophenonederivatives against SARS-CoV-2
by: Mebarka Ouassaf, et al.
Published: (2021-03-01)

Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas
by: Yu-Chieh Su, et al.
Published: (2022-12-01)

Upregulation of miR-214 Induced Radioresistance of Osteosarcoma by Targeting PHLDA2 via PI3K/Akt Signaling
by: Yi Li, et al.
Published: (2019-04-01)

DNA polymerase ζ suppresses the radiosensitivity of glioma cells by regulating the PI3K/AKT/mTOR pathway
by: Jiqiang Ding, et al.
Published: (2023-12-01)

A Circ-0007022/miR-338-3p/Neuropilin-1 Axis Reduces the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Activating Epithelial-To-Mesenchymal Transition and PI3K/AKT Pathway
by: Junpeng Zhang, et al.
Published: (2022-04-01)

PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors
by: Zeta Chow, et al.
Published: (2021-05-01)

Microwave hyperthermia enhances radiosensitization by decreasing DNA repair efficiency and inducing oxidative stress in PC3 prostatic adenocarcinoma cells
by: Yajun Wu, et al.
Published: (2024-12-01)

New insights into the in silico prediction of HIV protease resistance to nelfinavir.
by: Dinler A Antunes, et al.
Published: (2014-01-01)

Perfusion imaging and tissue biomarkers for colorectal cancer
by: Hill, E
Published: (2015)

Targeting PI3K and AMPKα Signaling Alone or in Combination to Enhance Radiosensitivity of Triple Negative Breast Cancer
by: Jeremy Johnson, et al.
Published: (2020-05-01)

Application of nanomedicine in radiotherapy sensitization
by: Xiaoyu Song, et al.
Published: (2023-02-01)

Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells
by: Kyung Hwan Kim, et al.
Published: (2020-09-01)

A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways
by: Lin Li, et al.
Published: (2021-10-01)

Radiosensitization to γ-Ray by Functional Inhibition of APOBEC3G
by: Ying Tong, et al.
Published: (2022-05-01)

Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity
by: Zhiru Gao, et al.
Published: (2023-05-01)

The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway
by: Xiaolong Tang, et al.
Published: (2020-03-01)